

Doç. Dr. COŞKUN ÖZER DEMİRTAŞ

Kişisel Bilgiler

E-posta: cdemirtas@marmara.edu.tr

Web: <https://avesis.marmara.edu.tr/cdemirtas>

Uluslararası Araştırmacı ID'leri

ORCID: 0000-0002-0004-2740

Publons / Web Of Science ResearcherID: AAD-7378-2021

Yoksis Araştırmacı ID: 190225

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- I. **Prevalence of metabolic dysfunction-associated steatotic liver disease and steatohepatitis in Türkiye: A forensic autopsy study**
Ergenc I., Kara E., Yilmaz M. E., DEMİRTAŞ C. Ö., Keklikkiran C., Das T., BÜYÜK Y., ÇELİKEL Ç., Asliyukse H., YILMAZ Y.
Heliyon, cilt.10, sa.15, 2024 (SCI-Expanded)
- II. **Radiological Quantification of Sarcopenic Obesity and its Role in Chronic Liver Disease Severity.**
Cimsit C., Kursun M., Demircioglu O., Dilber F., Demirtas C. O., Ergenc I.
Academic radiology, cilt.30, 2023 (SCI-Expanded)
- III. **Practicality and potential restrictions of unresectable hepatocellular carcinoma prognostic index**
DEMİRTAŞ C. Ö., Ricco G., ÖZDOĞAN O. C., BALTACIOĞLU F., ÖNEŞ T., YUMUK P. F., DULUNDU E., Uzun S., Colombatto P., Oliveri F., et al.
HEPATOLOGY COMMUNICATIONS, cilt.6, sa.12, ss.3600-3601, 2022 (SCI-Expanded)
- IV. **Preliminary results of the effectiveness and safety of Tenofovir Adefenamide Fumarate prophylaxis in HBV-infected individuals, who received chemo/immunosuppressive therapy**
GÜNDÜZ F., DURAK S., ÜNSAL Y., DEMİR M., Elik Z. M., YILDIRIM A. E., Mehdiyev S., ADANIR H., DEMİRTAŞ C. Ö., ÜÇBİLEK E., et al.
JOURNAL OF HEPATOLOGY, cilt.77, 2022 (SCI-Expanded)
- V. **Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders**
DEMİRTAŞ C. Ö., Ricco G., ÖZDOĞAN O. C., BALTACIOĞLU F., Ones T., YUMUK P. F., DULUNDU E., Uzun S., Colombatto P., Oliveri F., et al.
HEPATOLOGY COMMUNICATIONS, cilt.6, sa.3, ss.633-645, 2022 (SCI-Expanded)
- VI. **Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?**
Fulgenzi C. A. M., D'Alessio A., Ogunbiyi O., DEMİRTAŞ C. Ö., Gennari A., Cortellini A., Sharma R., Pinato D. J.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, cilt.31, ss.681-691, 2022 (SCI-Expanded)
- VII. **MODELLING THE DYNAMICS OF CANCER CELLS AND TUMOR VASCULATURE IN HCC PATIENTS TREATED WITH TKIs OR TACE**
Colombatto P., Damone F., Ricco G., Oliveri F., Civitano L., Romagnoli V., Cavallone D., DEMİRTAŞ C. Ö., Boraschi P., Scalise P., et al.
HEPATOLOGY, cilt.74, 2021 (SCI-Expanded)
- VIII. **Impact of COVID-19 Pandemic on Gastroenterology Fellowship Training in Turkey: A Prospective Nationwide Survey Study**
DEMİRTAŞ C. Ö., Vahabov C., Mustafayev F., Sahin T., PARLAK E.

TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.32, sa.10, ss.879-891, 2021 (SCI-Expanded)

- IX. **Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?**
DEMİRTAŞ C. Ö., Brunetto M. R.
WORLD JOURNAL OF GASTROENTEROLOGY, cilt.27, sa.33, ss.5536-5554, 2021 (SCI-Expanded)
- X. **Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study**
DEMİRTAŞ C. Ö., Tolu T., KEKLİKKIRAN Ç., ÖZDOĞAN O. C., GÜNDÜZ F.
TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.32, sa.8, ss.685-693, 2021 (SCI-Expanded)
- XI. **Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease**
KANİ H. T., DEMİRTAŞ C. Ö., KEKLİKKIRAN Ç., Ergenc I., Mehdiyev S., AKDENİZ E., YILMAZ Y.
TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.32, sa.8, ss.661-666, 2021 (SCI-Expanded)
- XII. **Proposal and validation of a novel scoring system for hepatocellular carcinomas beyond curability borders: Unresectable hepatocellular carcinoma prognostic index**
DEMİRTAŞ C. Ö., Ricco G., ÖZDOĞAN O. C., BALTAÇIOĞLU F., ÖNEŞ T., YUMUK P. F., DULUNDU E., Uzun S., Colombatto P., Oliveri F., et al.
JOURNAL OF HEPATOLOGY, cilt.75, 2021 (SCI-Expanded)
- XIII. **Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib**
Colombatto P., DEMİRTAŞ C. Ö., Ricco G., Civitano L., Boraschi P., Scalise P., Cavallone D., Oliveri F., Romagnoli V., Bleve P., et al.
CANCERS, cilt.13, sa.9, 2021 (SCI-Expanded)
- XIV. **Letter: Is female sex an independent predictor of favourable prognosis in hepatocellular carcinoma?**
Demirtas C. O., Gunduz F.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, cilt.52, ss.1765-1766, 2020 (SCI-Expanded)
- XV. **Myeloperoxidase and calprotectin; Any role as non-invasive markers for the prediction of inflammation and fibrosis in non-alcoholic steatohepatitis?**
Bicakci E., DEMİRTAŞ C. Ö., ÇELİKEL Ç., HAKLAR G., DUMAN D.
TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.31, sa.10, ss.681-687, 2020 (SCI-Expanded)
- XVI. **Validation and reliability of the Turkish version of the inflammatory bowel disease questionnaire for ulcerative colitis and Crohn's disease**
KANİ H. T., Ergenc I., Arikan H., Komesli Z., Seyrek B., DEMİRTAŞ C. Ö., ÖZEN ALAHDAB Y., Imeryuz N., ATUĞ Ö.
TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.31, sa.8, ss.566-572, 2020 (SCI-Expanded)
- XVII. **A large Turkish pedigree with multiple endocrine neoplasia type 1 syndrome carrying a rare mutation: c.1680_1683 del TGAG**
Demirtaş C. Ö., Ata P., Çetin A., Turkyılmaz A., Duman D.
TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.31, ss.508-514, 2020 (SCI-Expanded)
- XVIII. **The optimal controlled attenuation parameter cut-offs in hepatic steatosis grade differentiation by transient elastography (Fibroscan) in a sample of biopsy-proven non-alcoholic fatty liver disease patients**
Kaya E., BAKIR A., Sapmaz A. F., Kayyali T., Quatranji L., Çiftaslan A., Demirtas C. O., DEMİRTAŞ C. Ö., KANİ H. T., YILMAZ Y.
Hepatology International, cilt.13, ss.196, 2019 (SCI-Expanded)
- XIX. **Convenient chronic hepatitis B candidates for antiviral cessation and retreatment after relapse: When and who?**
DEMİRTAŞ C. Ö., ÖZDOĞAN O. C.
TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.29, sa.6, ss.720-721, 2018 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler

- I. **Evaluation of the effectiveness of drug-eluting transarterial chemoembolization in hepatocellular carcinoma**
ALAN A. M., ALAN Ö., ASADOV R., DEMİRTAŞ C. Ö., KANI H. T., YUMUK P. F., ÖZDOĞAN O. C., BALTACIOĞLU F., GÜNDÜZ F.
Hepatology forum, cilt.4, sa.2, ss.53-60, 2023 (Scopus)
- II. **The preliminary data of gene expressions and bioinformatics analysis of miR-146b-5p and miR-4510 in Turkish population in HBV related hepatocellular carcinoma**
BİRCAN KADIOĞLU D., DEMİRTAŞ C. Ö., PİRİM D., Gündüz F., EREN F.
Hepatology forum, 2023 (ESCI)
- III. **Characteristics of patients with hepatocellular carcinoma: A multicenter study**
Guzelbulut F., KARAOĞULLARINDAN Ü., AKKIZ H., ALTINTAŞ E., DEMİRTAŞ C. Ö., Bahadır O., KEKLİKKIRAN Ç., YILDIRIM A. E., Gumussoy M., Balci H. R., et al.
HEPATOLOGY FORUM, cilt.3, sa.3, ss.71-76, 2022 (ESCI)
- IV. **Programmed Cell Death 1 and Hepatocellular Carcinoma: An Epochal Story**
DEMİRTAŞ C. Ö., GÜNDÜZ F.
JOURNAL OF GASTROINTESTINAL CANCER, cilt.52, sa.4, ss.1217-1222, 2021 (ESCI)
- V. **Surveillance Strategies for Hepatocellular Carcinoma: Recent Advances and the Shifting Paradigm**
DEMİRTAŞ C. Ö., GÜNDÜZ F., ÖZDOĞAN O. C.
JOURNAL OF GASTROINTESTINAL CANCER, cilt.52, sa.4, ss.1336-1339, 2021 (ESCI)
- VI. **ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma**
DEMİRTAŞ C. Ö., 'Alessio A., Rimassa L., Sharma R., Pinato D. J.
JHEP REPORTS, cilt.3, sa.5, 2021 (ESCI)
- VII. **The natural course of gastric intestinal metaplasia in Turkish patients: A single-center observational cohort study**
DEMİRTAŞ C. Ö., Koldas M., Yılmaz M., Sahin M. Z., Soykuvvet M. T., ÇELİKEL Ç., GÜNDÜZ F.
MARMARA MEDICAL JOURNAL, cilt.34, sa.3, ss.229-233, 2021 (ESCI)
- VIII. **Surveillance of hepatocellular carcinoma in cirrhotic patients: Current knowledge and future directions**
Demirtas C. O., ÖZDOĞAN O. C.
HEPATOLOGY FORUM, cilt.1, sa.3, ss.112-118, 2020 (ESCI)
- IX. **The clinical and histological characteristics of patients with biopsy-proven non-alcoholic fatty liver disease in the absence of insulin resistance**
DEMİRTAŞ C. Ö., SAPMAZ A., GÜREL B. A., KIZMAZ H., ULU T., KARAKETİR Ş. G., YILMAZ Y.
Hepatology Forum, cilt.1, sa.3, ss.101-108, 2020 (Hakemli Dergi)
- X. **Metabolic-associated Fatty Liver Disease: Time to integrate ground-breaking new terminology to our clinical practice?**
DEMİRTAŞ C. Ö., YILMAZ Y.
Hepatology Forum, cilt.1, sa.3, ss.79-81, 2020 (Hakemli Dergi)

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

- I. **"The gene expressions and bioinformatics analysis of miR-146b-5p and miR-4510 in Hepatocellular Carcinoma"**
BİRCAN KADIOĞLU D., DEMİRTAŞ C. Ö., PİRİM D., Gündüz F., EREN F.
EASL Liver Cancer Summit, Estoril, Portekiz, 20 Nisan 2023, ss.134-135
- II. **ARTERIAL STIFFNESS IS INDEPENDENTLY ASSOCIATED WITH LIVER STIFFNESS IN BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE: A TRANSIENT ELASTOGRAPHY STUDY**
Bilgin B. O., SÜNÜL M., Kani H. T., Demirtas C. O., KEKLİKKIRAN Ç., YILMAZ Y.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting,
Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70

III. USEFULNESS OF ENDOSCOPIC ULTRASONOGRAPHY ELASTOGRAPHY (EUS-E) TO MEASURE LIVER STIFFNESS

Duman D. G., Alahdab Y., Demirtas C. O., YILMAZ Y., GÜNDÜZ F.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting,
Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70

IV. Annual contrast-enhanced MRI is highly effective in the surveillance of hepatocellular carcinoma in cirrhotic patients

DEMİRTAŞ C. Ö., GÜNDÜZ F., TÜNEY D., BALTAÇIOĞLU F., ÖZEN ALAHDAB Y., ÖZDOĞAN O. C.

International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver
(EASL), Vienna, Avusturya, 10 - 14 Nisan 2019, cilt.70

Metrikler

Yayın: 34

Atf (WoS): 8

Atf (Scopus): 16

H-İndeks (WoS): 2

H-İndeks (Scopus): 3

Akademi Dışı Deneyim

ADANA POZANTI 80. YIL DEVLET HASTANESİ